Infographic: “Planet Trial: Intravitreal aflibercept monotherapy for Polypoidal Choroidal Vasculopathy (PCV)”
Document Type
Article
Publication Date
6-1-2022
Abstract
PCV Polypoidal choroidal vasculopathy, IAI Intravitreal aflibercept monotherapy1,2, rPDT rescue Photodynamic therapy, ETDRS Early treatment diabetic retinopathy study, ICG indocyanine green angiography.
Keywords
Angiogenesis inhibitors, Choroid, Data visualization, Fluorescein angiography, Humans, Intravitreal injections, Planets, Polyps, Receptors, Vascular endothelial growth factor, Recombinant fusion proteins, Tomography, optical coherence, Aflibercept, Aflibercept, Angiogenesis inhibitor, Fusion protein, Vasculotropin receptor, Adult, Article, Best corrected visual acuity, Controlled study, Double blind procedure, Drug efficacy, Drug safety, Female, Human, Loading drug dose, Major clinical study, Male, Middle aged, Monotherapy, Phase 3 clinical trial, Phase 4 clinical trial, Photodynamic therapy, Polypoidal choroidal vasculopathy, Randomized controlled trial, astronomy, Choroid, Fluorescence angiography, Intravitreal drug administration, Optical coherence tomography, Polyp
Divisions
ophthalmplogy
Funders
None
Publication Title
Eye
Volume
36
Issue
6
Publisher
Springer Nature